Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Knowing when to start saving for retirement is crucial for building a solid financial foundation. Explore the ideal timing for your savings.
25,408 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Argus boosts Exxon Mobil's target to $169, signaling confidence in higher 2026 output from Permian and Guyana and a r...
Home builders are embedding smart security: builder technology at scale, driving real-time monitoring, interoperabili...
Solesence kicked off 2026 with a solid Q1 showing across core segments. This deep dive breaks down the numbers, what ...
A pivotal moment in monetary policy unfolds as Warsh is confirmed to lead the Fed, with investors weighing how his st...
Bank of America initiates coverage on Salesforce with an Underperform rating and a $160 price target, highlighting un...
Speculative AI-driven forecasts tied to Sam Altman's tools predict altman chatgpt predicts incredible upside for DOGE...
Ford’s stock closed at its highest level in three years, powered by AI tie-ups, improving European margins, and robus...
A major corporate AI experiment reveals the real obstacles to change are human—habits, time, and permission—posing br...
XRP's price fell in the first quarter, but XRP Ledger usage climbed sharply as stablecoins and tokenized assets expan...
A wave of AI-driven market chatter claims Sam Altman’s ChatGPT-style model is forecasting a sharp XRP rally over the ...
Arthur Hayes faces swift backlash after signaling bullish bets on several coins, only to exit large positions soon af...